계명대학교 의학도서관 Repository

Changes in Clinical Activity, Serum Autoantibody Levels, and Chorioretinal Vessels After Systemic Glucocorticoid Therapy in Thyroid Eye Disease

Metadata Downloads
Author(s)
Jaekyoung LeeDong Cheol Lee
Keimyung Author(s)
Lee, Dong Cheol
Department
Dept. of Ophthalmology (안과학)
Journal Title
Ophthalmol Ther
Issued Date
2023
Volume
12
Issue
4
Keyword
Chorioretinal capillary perfusionChoroidal thicknessClinical activity scoreExtraocular muscle thicknessRetinal blood vesselSystemic glucocorticoidThyroid eye diseaseThyroid-stimulating hormone receptor antibodyThyroid-stimulating immunoglobulin
Abstract
Introduction:
The aim of this study was to investigate changes in the Clinical Activity Score, serum thyroid-stimulating hormone receptor antibody and thyroid-stimulating immunoglobulin levels, chorioretinal blood vessels, and extraocular muscle thickness in patients with thyroid eye disease following systemic steroid treatment.

Methods:
This prospective observational study enrolled 57 patients with active thyroid eye disease who received systemic intravenous glucocorticoids for 12 weeks. Demographics, clinical activity scores, optical coherence tomography images, and serum thyroid-stimulating immunoglobulin and thyroid-stimulating hormone receptor antibody levels were assessed at baseline, at 6 and 12 weeks after intravenous (IV) GC therapy initiation, and 2 months after IV GC therapy termination. The extraocular muscle thickness, choroidal thickness, and choroidal vascularity index were measured.

Results:
The clinical activity scores showed a significant decrease. Serum thyroid-stimulating immunoglobulin levels dropped continuously for 2 months. The thyroid-stimulating hormone receptor antibody level decreased until 12 weeks after treatment but returned to within the normal range in 75% of patients after 77 and 126 days, respectively. The choroidal thickness decreased at all time points. The thickness of the medial and inferior rectus muscles decreased at 2 months after treatment. The clinical activity score decreased to < 3 points in 50% of patients after 78 days.

Conclusion:
Intravenous glucocorticoid therapy improved the clinical activity score, chorioretinal blood flow, and extraocular muscle thickness. The serum autoantibody levels were normalized in patients with active thyroid eye disease 2 months after IV GC termination. The serum thyroid-stimulating immunoglobulin and thyroid-stimulating hormone receptor antibody levels correlated with restoration of chorioretinal capillary perfusion and improved clinical symptoms and muscle thickness. Non-invasive optical coherence tomography findings and serologic factors predict the response to intravenous glucocorticoid therapy.
Keimyung Author(s)(Kor)
이동철
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
2193-8245
Source
https://link.springer.com/article/10.1007/s40123-023-00696-y
DOI
10.1007/s40123-023-00696-y
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/45016
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Ophthalmology (안과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.